Novacyt Stock

Novacyt ROA

The Return on Assets (ROA) of Novacyt (ALNOV.PA) as of Aug 22, 2026 is -59.12 %. In the previous year, Return on Assets (ROA) was -21.14 % — a change of 179.63% (lower).

ROA

-59.12 %

YoY

179.63%

Last updated:

In 2026, Novacyt's return on assets (ROA) was -59.12 %, a 179.63% increase from the -21.14 % ROA in the previous year.

The Novacyt ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2017
-16.38 GBP
Jan 1, 2018
-14.36 GBP
Jan 1, 2019
-21.67 GBP
Jan 1, 2020
56.52 GBP
Jan 1, 2021
-5.30 GBP
Jan 1, 2022
-18.26 GBP
Jan 1, 2023
-21.14 GBP
Jan 1, 2024
-59.12 GBP
The Novacyt ROA history
YEARROAYoY
-59.12 %+179.63%
-21.14 %+15.78%
-18.26 %+244.83%
-5.30 %-109.37%
56.52 %-360.81%
-21.67 %+50.88%
-14.36 %-12.31%
-16.38 %-12.68%
-18.76 %-76.93%
-81.30 %+453.82%
-14.68 %—
Access this data via the Eulerpool API
Get Free API Key

Novacyt Stock analysis

What does Novacyt do? Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. The company was founded in 2006 and has experienced impressive growth since then. Its headquarters are located in Paris. Novacyt's business model revolves around the development and marketing of diagnostic products and technologies, particularly molecular diagnostic kits and reagents used for identification and quantification of microorganisms, viruses, and genetic differences. These products are commonly used in medical research, clinical diagnostics, and environmental analysis. Novacyt is divided into several divisions, each offering different products and services. Its diagnostic business specializes in the research, development, and marketing of molecular diagnostic kits, including the Primerdesign Kits specifically designed for COVID-19 identification. The company also provides laboratory and service offerings, such as DNA sequencing, qPCR analysis, sample preparation, and PCR disinfection. Additionally, Novacyt offers various diagnostic tests capable of detecting genetic differences and mutations. Its PathFlow division focuses on improving the process from diagnosis to therapy and follow-up, particularly for oncology patients. In response to the COVID-19 pandemic, Novacyt quickly launched a PCR test kit for COVID-19, which has been approved in numerous countries worldwide. Novacyt has successfully established itself as a key player in the fight against the pandemic. In summary, Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. Through its divisions, the company ensures the optimal utilization of molecular diagnostic tests. Novacyt has become an important player in the fight against the pandemic through its rapid response and development of molecular diagnostic kits for COVID-19, establishing itself as a reliable and innovative partner for medical research and clinical diagnostics. Novacyt is one of the most popular companies on Eulerpool.

ROA Details

Understanding Novacyt's Return on Assets (ROA)

Novacyt's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Novacyt's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Novacyt's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Novacyt’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Novacyt stock

Return on Assets (ROA) of Novacyt is -59.12 % in 2026.

Return on Assets (ROA) of Novacyt changed from -21.14 % to -59.12 %, representing a 179.63% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Novacyt since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Novacyt with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API
Get Free API Key

Profitability — Novacyt

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Novacyt